Denmark's MPI To Develop Cancer Drug Response Tests on Affy Platform | GenomeWeb
NEW YORK (GenomeWeb News) – Affymetrix said today that Medical Prognosis Institute, a cancer diagnostic firm based in Denmark, will use the Affy microarray platform to develop drug sensitivity prediction and prognostic tools for patients with cancer.
 
Under the terms of the “Powered by Affymetrix” agreement, MPI gains non-exclusive access to Affy’s technology to develop and commercialize tools that will identify patients likely to respond to anti-cancer drugs.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.